• Vaccine Name: vFP89-H5
• Target Pathogen: Influenza virus
• Target Disease: Influenza (flu)
• Vaccine Ontology ID: VO_0004620
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• HA gene engineering:
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001040
• Preparation: Recombinant vaccine (vNDV-H5) encoding an optimized synthetic haemagglutinin gene from a clade 2.2.1 H5N1 highly pathogenic (HP) avian influenza virus (AIV), either as a single administration or as a boost following a prime inoculation with a fowlpox vectored vaccine (vFP89) encoding a different H5 HP haemagglutinin from an Irish H5N8 strain (Niqueux et al., 2013).
• Immunization Route: Intramuscular injection (i.m.)

Ducks Response

• Vaccination Protocol: Ducks were divided into two groups and one group had vFP89 vaccine was inoculated subcutaneously in the back of the neck, at 104.5 TCID50/0.2 ml dose. The second group hadRe-5 vaccine was injected subcutaneously as a single 0.5 ml dose (Niqueux et al., 2013).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: HPAIV challenge was done in a large BSL3 isolator at 43, 65 or 86 days of age respectively. All vaccinated or control ducks were inoculated by oculo-nasal instillation with 100 μl of a virus dilution containing 106 EID50 of HPAIV H5N1 A/mute swan/France/06299/06 strain, prepared in phosphate-buffered saline as previously described (Niqueux et al., 2013).
• Efficacy: Only the prime-boost vaccination (vFP89+vNDV-H5) was still fully protecting Muscovy ducks against disease and mortality at 12 weeks of age. Reduction of oropharyngeal shedding levels was also constantly observed from the onset of the follow-up at 2.5 or three days post-infection in vaccinated ducks compared to unvaccinated controls, and was significantly more important for vFP89+vNDV-H5 vaccination than for vNDV-H5 alone (Niqueux et al., 2013).